You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameGuanabenz
Accession NumberDB00629  (APRD00487)
TypeSmall Molecule
GroupsApproved
DescriptionAn alpha-2 selective adrenergic agonist used as an antihypertensive agent. [PubChem]
Structure
Thumb
Synonyms
Guanabenz
Guanabenzo
Guanabenzum
WY-8678
Wytensin
External Identifiers
  • BR 750
  • FLA 137
  • GBZ
  • SD 15468
  • Wy 8678
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
LisapresLibbs
RexiteneL.P.B.
WytensAlfresa Pharma
WytensinWyeth
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Guanabenz Acetate
23256-50-0
Thumb
  • InChI Key: MCSPBPXATWBACD-GAYQJXMFSA-N
  • Monoisotopic Mass: 290.033731062
  • Average Mass: 291.134
DBSALT000649
Categories
UNIIGGD30112WC
CAS number5051-62-7
WeightAverage: 231.082
Monoisotopic: 230.01260169
Chemical FormulaC8H8Cl2N4
InChI KeyWDZVGELJXXEGPV-YIXHJXPBSA-N
InChI
InChI=1S/C8H8Cl2N4/c9-6-2-1-3-7(10)5(6)4-13-14-8(11)12/h1-4H,(H4,11,12,14)/b13-4+
IUPAC Name
2-{[(2,6-dichlorophenyl)methylidene]amino}guanidine
SMILES
NC(N)=NN=CC1=C(Cl)C=CC=C1Cl
Pharmacology
IndicationFor management of High blood pressure
Structured Indications Not Available
PharmacodynamicsGuanabenz, a centrally acting α-2 adrenergic agonist, is indicated for treatment of hypertension.
Mechanism of actionGuanabenz's antihypertensive effect is thought to be due to central alpha-adrenergic stimulation, which results in a decreased sympathetic outflow to the heart, kidneys, and peripheral vasculature in addition to a decreased systolic and diastolic blood pressure and a slight slowing of pulse rate. Chronic administration of guanabenz also causes a decrease in peripheral vascular resistance.
TargetKindPharmacological actionActionsOrganismUniProt ID
Alpha-2A adrenergic receptorProteinyes
agonist
HumanP08913 details
Alpha-2B adrenergic receptorProteinunknown
binder
HumanP18089 details
Related Articles
AbsorptionApproximately 75% absorbed from gastrointestinal tract
Volume of distributionNot Available
Protein binding90%
Metabolism

Hepatic

Route of eliminationNot Available
Half life6 hours.
ClearanceNot Available
ToxicityExcessive contraction of the pupils, irritability, low blood pressure, sleepiness, slow heartbeat, sluggishness
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Guanabenz.Experimental
AbirateroneThe serum concentration of Guanabenz can be increased when it is combined with Abiraterone.Approved
AcebutololGuanabenz may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Guanabenz.Approved, Investigational
AliskirenGuanabenz may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlprenololGuanabenz may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Withdrawn
AmbrisentanGuanabenz may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineGuanabenz may increase the hypotensive activities of Amifostine.Approved, Investigational
AmineptineAmineptine may decrease the antihypertensive activities of Guanabenz.Illicit, Withdrawn
AmitriptylineAmitriptyline may decrease the antihypertensive activities of Guanabenz.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Guanabenz.Approved
Aop200704Guanabenz may increase the atrioventricular blocking (AV block) activities of Aop200704.Investigational
ArotinololGuanabenz may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
AtenololGuanabenz may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
AzithromycinThe metabolism of Guanabenz can be decreased when combined with Azithromycin.Approved
BefunololGuanabenz may increase the atrioventricular blocking (AV block) activities of Befunolol.Experimental
BenazeprilBenazepril may increase the hypotensive activities of Guanabenz.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Guanabenz.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Guanabenz.Withdrawn
Benzylpenicilloyl PolylysineGuanabenz may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilGuanabenz may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololGuanabenz may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
BethanidineBethanidine may increase the hypotensive activities of Guanabenz.Approved
BevantololGuanabenz may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
BimatoprostGuanabenz may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololGuanabenz may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
BopindololGuanabenz may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
BortezomibThe metabolism of Guanabenz can be decreased when combined with Bortezomib.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Guanabenz.Approved, Investigational
BretyliumGuanabenz may increase the hypotensive activities of Bretylium.Approved
BrimonidineBrimonidine may increase the hypotensive activities of Guanabenz.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Guanabenz.Approved
BromocriptineBromocriptine may increase the hypertensive activities of Guanabenz.Approved, Investigational
BucindololGuanabenz may increase the atrioventricular blocking (AV block) activities of Bucindolol.Investigational
BufuralolGuanabenz may increase the atrioventricular blocking (AV block) activities of Bufuralol.Experimental, Investigational
BupranololGuanabenz may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
CabergolineCabergoline may increase the hypertensive activities of Guanabenz.Approved
CaffeineThe metabolism of Guanabenz can be decreased when combined with Caffeine.Approved
CandesartanGuanabenz may increase the hypotensive activities of Candesartan.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Guanabenz.Experimental
CaptoprilGuanabenz may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe metabolism of Guanabenz can be increased when combined with Carbamazepine.Approved, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Guanabenz.Withdrawn
CarteololGuanabenz may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
CarvedilolGuanabenz may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
CeliprololGuanabenz may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
ChlorothiazideGuanabenz may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Guanabenz.Approved
CilazaprilGuanabenz may increase the hypotensive activities of Cilazapril.Approved
CitalopramThe metabolism of Guanabenz can be decreased when combined with Citalopram.Approved
ClomipramineClomipramine may decrease the antihypertensive activities of Guanabenz.Approved, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Guanabenz.Approved
ClotrimazoleThe metabolism of Guanabenz can be decreased when combined with Clotrimazole.Approved, Vet Approved
CryptenamineGuanabenz may increase the hypotensive activities of Cryptenamine.Approved
CyclobenzaprineCyclobenzaprine may decrease the antihypertensive activities of Guanabenz.Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Guanabenz.Approved
Cyproterone acetateThe serum concentration of Guanabenz can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DebrisoquinGuanabenz may increase the hypotensive activities of Debrisoquin.Approved
DeferasiroxThe serum concentration of Guanabenz can be increased when it is combined with Deferasirox.Approved, Investigational
DeserpidineGuanabenz may increase the hypotensive activities of Deserpidine.Approved
DesipramineDesipramine may decrease the antihypertensive activities of Guanabenz.Approved
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Guanabenz.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Guanabenz.Approved
DihydralazineGuanabenz may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineDihydroergotamine may increase the hypertensive activities of Guanabenz.Approved
DiltiazemDiltiazem may increase the hypotensive activities of Guanabenz.Approved
DorzolamideGuanabenz may increase the hypotensive activities of Dorzolamide.Approved
DosulepinDosulepin may decrease the antihypertensive activities of Guanabenz.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Guanabenz.Approved
DoxepinDoxepin may decrease the antihypertensive activities of Guanabenz.Approved
DuloxetineDuloxetine may increase the tachycardic activities of Guanabenz.Approved
EfonidipineGuanabenz may increase the hypotensive activities of Efonidipine.Approved
EnalaprilEnalapril may increase the hypotensive activities of Guanabenz.Approved, Vet Approved
EnalaprilatGuanabenz may increase the hypotensive activities of Enalaprilat.Approved
EpoprostenolGuanabenz may increase the hypotensive activities of Epoprostenol.Approved
EprosartanGuanabenz may increase the hypotensive activities of Eprosartan.Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive activities of Guanabenz.Approved
ErgonovineErgonovine may increase the hypertensive activities of Guanabenz.Approved
ErgotamineErgotamine may increase the hypertensive activities of Guanabenz.Approved
EsmirtazapineEsmirtazapine may decrease the antihypertensive activities of Guanabenz.Investigational
EsmololGuanabenz may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
FelodipineGuanabenz may increase the hypotensive activities of Felodipine.Approved, Investigational
FenoldopamGuanabenz may increase the hypotensive activities of Fenoldopam.Approved
FluvoxamineThe metabolism of Guanabenz can be decreased when combined with Fluvoxamine.Approved, Investigational
FosinoprilFosinopril may increase the hypotensive activities of Guanabenz.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Guanabenz.Approved, Vet Approved
GuanadrelGuanadrel may increase the hypotensive activities of Guanabenz.Approved
GuanethidineGuanabenz may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanabenz may increase the hypotensive activities of Guanfacine.Approved, Investigational
HexamethoniumGuanabenz may increase the hypotensive activities of Hexamethonium.Experimental
HyaluronidaseHyaluronidase may increase the vasoconstricting activities of Guanabenz.Approved, Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Guanabenz.Approved
HydralazineGuanabenz may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideGuanabenz may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideGuanabenz may increase the hypotensive activities of Hydroflumethiazide.Approved
IloprostIloprost may increase the hypotensive activities of Guanabenz.Approved, Investigational
ImidaprilGuanabenz may increase the hypotensive activities of Imidapril.Investigational
ImipramineImipramine may decrease the antihypertensive activities of Guanabenz.Approved
IndapamideGuanabenz may increase the hypotensive activities of Indapamide.Approved
IndenololGuanabenz may increase the atrioventricular blocking (AV block) activities of Indenolol.Withdrawn
IndoraminGuanabenz may increase the hypotensive activities of Indoramin.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Guanabenz.Approved
IproclozideIproclozide may increase the hypotensive activities of Guanabenz.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Guanabenz.Withdrawn
IrbesartanGuanabenz may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Guanabenz.Approved
IsradipineIsradipine may increase the hypotensive activities of Guanabenz.Approved
KetanserinGuanabenz may increase the hypotensive activities of Ketanserin.Investigational
LabetalolGuanabenz may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
LacidipineGuanabenz may increase the hypotensive activities of Lacidipine.Approved
LatanoprostGuanabenz may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Guanabenz.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Guanabenz.Approved
LidocaineThe metabolism of Guanabenz can be decreased when combined with Lidocaine.Approved, Vet Approved
LisinoprilGuanabenz may increase the hypotensive activities of Lisinopril.Approved, Investigational
LofexidineGuanabenz may increase the hypotensive activities of Lofexidine.Approved, Investigational
LosartanGuanabenz may increase the hypotensive activities of Losartan.Approved
MacitentanGuanabenz may increase the hypotensive activities of Macitentan.Approved
ManidipineGuanabenz may increase the hypotensive activities of Manidipine.Approved
MebanazineMebanazine may increase the hypotensive activities of Guanabenz.Withdrawn
MecamylamineGuanabenz may increase the hypotensive activities of Mecamylamine.Approved
MethyldopaGuanabenz may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Guanabenz.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Guanabenz.Approved, Investigational
MetipranololGuanabenz may increase the hypotensive activities of Metipranolol.Approved
MetolazoneMetolazone may increase the hypotensive activities of Guanabenz.Approved
MetoprololGuanabenz may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
MetyrosineGuanabenz may increase the hypotensive activities of Metyrosine.Approved
MexiletineThe metabolism of Guanabenz can be decreased when combined with Mexiletine.Approved
MianserinThe therapeutic efficacy of Guanabenz can be decreased when used in combination with Mianserin.Approved
MibefradilGuanabenz may increase the hypotensive activities of Mibefradil.Withdrawn
MilnacipranMilnacipran may increase the tachycardic activities of Guanabenz.Approved
MinaprineMinaprine may increase the hypotensive activities of Guanabenz.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Guanabenz.Approved
MirtazapineMirtazapine may decrease the antihypertensive activities of Guanabenz.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Guanabenz.Approved
MoexiprilGuanabenz may increase the hypotensive activities of Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Guanabenz.Approved
MoxonidineGuanabenz may increase the hypotensive activities of Moxonidine.Approved
NadololGuanabenz may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
NaftopidilGuanabenz may increase the hypotensive activities of Naftopidil.Investigational
NebivololGuanabenz may increase the hypotensive activities of Nebivolol.Approved, Investigational
NevirapineThe metabolism of Guanabenz can be decreased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Guanabenz.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Guanabenz.Approved
NicorandilGuanabenz may increase the hypotensive activities of Nicorandil.Approved
NiguldipineGuanabenz may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineGuanabenz may increase the hypotensive activities of Nilvadipine.Approved
NimodipineNimodipine may increase the hypotensive activities of Guanabenz.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Guanabenz.Approved
NitrendipineGuanabenz may increase the hypotensive activities of Nitrendipine.Approved
NitroprussideNitroprusside may increase the hypotensive activities of Guanabenz.Approved
NortriptylineNortriptyline may decrease the antihypertensive activities of Guanabenz.Approved
ObinutuzumabGuanabenz may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Guanabenz.Withdrawn
OlmesartanOlmesartan may increase the hypotensive activities of Guanabenz.Approved, Investigational
OmapatrilatGuanabenz may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolOpipramol may decrease the antihypertensive activities of Guanabenz.Investigational
OsimertinibThe serum concentration of Guanabenz can be decreased when it is combined with Osimertinib.Approved
OxprenololGuanabenz may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
PargylinePargyline may increase the hypotensive activities of Guanabenz.Approved
Peginterferon alfa-2bThe serum concentration of Guanabenz can be increased when it is combined with Peginterferon alfa-2b.Approved
PenbutololGuanabenz may increase the atrioventricular blocking (AV block) activities of Penbutolol.Approved, Investigational
PentoliniumGuanabenz may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Guanabenz.Approved, Investigational
PerindoprilGuanabenz may increase the hypotensive activities of Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Guanabenz.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Guanabenz.Withdrawn
PhenobarbitalThe metabolism of Guanabenz can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineGuanabenz may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Guanabenz.Withdrawn
PhentolamineGuanabenz may increase the hypotensive activities of Phentolamine.Approved
PinacidilGuanabenz may increase the hypotensive activities of Pinacidil.Withdrawn
PindololGuanabenz may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
PirlindolePirlindole may increase the hypotensive activities of Guanabenz.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Guanabenz.Withdrawn
PolythiazideGuanabenz may increase the hypotensive activities of Polythiazide.Approved
PractololGuanabenz may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
PrazosinPrazosin may increase the hypotensive activities of Guanabenz.Approved
PrimidoneThe metabolism of Guanabenz can be increased when combined with Primidone.Approved, Vet Approved
PropranololGuanabenz may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
ProtriptylineProtriptyline may decrease the antihypertensive activities of Guanabenz.Approved
QuinaprilGuanabenz may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Guanabenz.Approved
RamiprilRamipril may increase the hypotensive activities of Guanabenz.Approved
RasagilineRasagiline may increase the hypotensive activities of Guanabenz.Approved
RemikirenRemikiren may increase the hypotensive activities of Guanabenz.Approved
RescinnamineGuanabenz may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Guanabenz.Approved
RifampicinThe metabolism of Guanabenz can be increased when combined with Rifampicin.Approved
RilmenidineGuanabenz may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatGuanabenz may increase the hypotensive activities of Riociguat.Approved
RituximabGuanabenz may increase the hypotensive activities of Rituximab.Approved
RopiniroleThe metabolism of Guanabenz can be decreased when combined with Ropinirole.Approved, Investigational
SafrazineSafrazine may increase the hypotensive activities of Guanabenz.Withdrawn
SaprisartanGuanabenz may increase the hypotensive activities of Saprisartan.Experimental
SelegilineSelegiline may increase the hypotensive activities of Guanabenz.Approved, Investigational, Vet Approved
SelexipagGuanabenz may increase the hypotensive activities of Selexipag.Approved
SildenafilSildenafil may increase the antihypertensive activities of Guanabenz.Approved, Investigational
SilodosinSilodosin may decrease the vasoconstricting activities of Guanabenz.Approved
SimeprevirThe metabolism of Guanabenz can be decreased when combined with Simeprevir.Approved
SitaxentanGuanabenz may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SotalolGuanabenz may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
SpiraprilGuanabenz may increase the hypotensive activities of Spirapril.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Guanabenz.Approved
TadalafilTadalafil may increase the antihypertensive activities of Guanabenz.Approved, Investigational
TamsulosinTamsulosin may decrease the vasoconstricting activities of Guanabenz.Approved, Investigational
TelmisartanGuanabenz may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilGuanabenz may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenofovirThe metabolism of Guanabenz can be decreased when combined with Tenofovir.Approved, Investigational
TerazosinTerazosin may decrease the vasoconstricting activities of Guanabenz.Approved
TeriflunomideThe serum concentration of Guanabenz can be decreased when it is combined with Teriflunomide.Approved
TerlipressinGuanabenz may increase the hypotensive activities of Terlipressin.Approved, Investigational
TheophyllineThe metabolism of Guanabenz can be decreased when combined with Theophylline.Approved
TianeptineTianeptine may decrease the antihypertensive activities of Guanabenz.Approved
TiboloneGuanabenz may increase the hypotensive activities of Tibolone.Approved
TiclopidineThe metabolism of Guanabenz can be decreased when combined with Ticlopidine.Approved
TicrynafenGuanabenz may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololGuanabenz may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
TolazolineGuanabenz may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
ToloxatoneToloxatone may increase the hypotensive activities of Guanabenz.Approved
TorasemideTorasemide may increase the hypotensive activities of Guanabenz.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Guanabenz.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Guanabenz.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Guanabenz.Approved
TravoprostTravoprost may increase the hypotensive activities of Guanabenz.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Guanabenz.Approved, Investigational
TrichlormethiazideGuanabenz may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinGuanabenz may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanGuanabenz may increase the hypotensive activities of Trimethaphan.Approved
TrimipramineTrimipramine may decrease the antihypertensive activities of Guanabenz.Approved
UdenafilUdenafil may increase the antihypertensive activities of Guanabenz.Approved, Investigational
UnoprostoneGuanabenz may increase the hypotensive activities of Unoprostone.Approved
ValsartanValsartan may increase the hypotensive activities of Guanabenz.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Guanabenz.Approved
VemurafenibThe serum concentration of Guanabenz can be increased when it is combined with Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the tachycardic activities of Guanabenz.Approved
VinpocetineGuanabenz may increase the hypotensive activities of Vinpocetine.Investigational
XylometazolineGuanabenz may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Guanabenz.Approved, Vet Approved
Food InteractionsNot Available
References
Synthesis Reference

British Patent 1,019,120.

General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (219 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9921
Blood Brain Barrier+0.8593
Caco-2 permeable+0.8867
P-glycoprotein substrateNon-substrate0.6838
P-glycoprotein inhibitor INon-inhibitor0.9248
P-glycoprotein inhibitor IINon-inhibitor0.9857
Renal organic cation transporterNon-inhibitor0.6424
CYP450 2C9 substrateNon-substrate0.8798
CYP450 2D6 substrateNon-substrate0.9003
CYP450 3A4 substrateNon-substrate0.7563
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.925
CYP450 2D6 inhibitorInhibitor0.884
CYP450 2C19 inhibitorNon-inhibitor0.9158
CYP450 3A4 inhibitorNon-inhibitor0.9135
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8825
Ames testNon AMES toxic0.618
CarcinogenicityNon-carcinogens0.6862
BiodegradationNot ready biodegradable0.9972
Rat acute toxicity2.8555 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8927
hERG inhibition (predictor II)Non-inhibitor0.9652
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Sandoz inc
  • Teva pharmaceuticals usa
  • Watson laboratories inc
  • Wyeth ayerst laboratories
Packagers
Dosage formsNot Available
Prices
Unit descriptionCostUnit
Guanabenz acetate 8 mg tablet2.13USD tablet
Guanabenz acetate 4 mg tablet1.07USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point225-227British Patent 1,019,120.
logP3.2Not Available
Caco2 permeability-4.5ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0889 mg/mLALOGPS
logP2.25ALOGPS
logP1.71ChemAxon
logS-3.4ALOGPS
pKa (Strongest Basic)6.82ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area76.76 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity58.15 m3·mol-1ChemAxon
Polarizability21.58 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dichlorobenzenes. These are compounds containing a benzene with exactly two chlorine atoms attached to it.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassHalobenzenes
Direct ParentDichlorobenzenes
Alternative Parents
Substituents
  • 1,3-dichlorobenzene
  • Aryl halide
  • Aryl chloride
  • Guanidine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Piletz JE, Sletten K: Nonadrenergic imidazoline binding sites on human platelets. J Pharmacol Exp Ther. 1993 Dec;267(3):1493-502. [PubMed:8263811 ]
  2. Bockman CS, Jeffries WB, Abel PW: Binding and functional characterization of alpha-2 adrenergic receptor subtypes on pig vascular endothelium. J Pharmacol Exp Ther. 1993 Dec;267(3):1126-33. [PubMed:7903385 ]
  3. Bockman CS, Gonzalez-Cabrera I, Abel PW: Alpha-2 adrenoceptor subtype causing nitric oxide-mediated vascular relaxation in rats. J Pharmacol Exp Ther. 1996 Sep;278(3):1235-43. [PubMed:8819507 ]
  4. Galeotti N, Bartolini A, Ghelardini C: Alpha-2 agonist-induced memory impairment is mediated by the alpha-2A-adrenoceptor subtype. Behav Brain Res. 2004 Aug 31;153(2):409-17. [PubMed:15265636 ]
  5. van Zwieten PA: Centrally acting antihypertensives: a renaissance of interest. Mechanisms and haemodynamics. J Hypertens Suppl. 1997 Jan;15(1):S3-8. [PubMed:9050980 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Uhlen S, Wikberg JE: Delineation of rat kidney alpha 2A- and alpha 2B-adrenoceptors with [3H]RX821002 radioligand binding: computer modelling reveals that guanfacine is an alpha 2A-selective compound. Eur J Pharmacol. 1991 Sep 17;202(2):235-43. [PubMed:1666366 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Wang B, Zhou SF: Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218. [PubMed:19754423 ]
  2. Clement B, Demesmaeker M: Formation of guanoxabenz from guanabenz in human liver. A new metabolic marker for CYP1A2. Drug Metab Dispos. 1997 Nov;25(11):1266-71. [PubMed:9351903 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 11:11